OncoSec Medical Inc (ONCSQ)

[$$$eeker]

$ONCS .461 pr from 1/14/14 Buying Opportunity in OncoSec Medical as Catalysts Approach
Earlier this morning, OncoSec Medical (ONCS.PK) announced its 2014 strategic update. The update provided a list of some of the upcoming events/catalysts that investors could expect. It appeared to have been a positive press release but shares dropped by as much as 15 percent before rebounding. The drop likely occurred because of investor impatience. Several investors may have been expecting a data release. Today’s sell-off reminds me of the age old adage that, “The stock market is a mechanism that transfers wealth from the impatient to the patient.” In order to be successful in the stock market, investors must know when to recognize value. After today’s sell-off, OncoSec Medical is extremely undervalued.

OncoSec Medical is a development-stage biotechnology focused on becoming the global leader in skin cancer treatment. In order to accomplish this, the company is focusing its efforts on immunotherapy, specifically, electroporation. Electroporation is the process of introducing DNA or chromosomes into bacteria or other cells using a pulse of electricity to briefly open the pores in the cell membranes. OncoSec Medical is evaluating this approach in several clinical trials which was the focus of today’s strategic update.

The strategic update contained several important pieces of information that investors should be aware of. One of the updates that stood out to me was the recent hiring of Dr. Robert Pierce, the new Chief Medical Officer “CMO” of OncoSec. Dr. Robert Pierce was the former Merck (NYSE:MRK) Research Labs Executive Director and member of the global anti-PD-1 development team. Over the past couple of months, anti-PD-1’s have been gaining a significant amount of attention in the medical community. The hiring of Dr. Robert Pierce adds significant credibility to OncoSec’s platform.
http://bit.ly/1arVYU8